tradingkey.logo
tradingkey.logo
Suchen

Zymeworks Inc

ZYME
Zur Watchlist hinzufügen
27.500USD
-0.065-0.24%
Handelsschluss 09-23 16:00ET
1.97BMarktkapitalisierung
VerlustKGV TTM

Über Zymeworks Inc Unternehmen

Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

Zymeworks Inc Profil

BörsenkürzelZYME
Name des UnternehmensZymeworks Inc
IPO-datumJun 24, 2019
CEOGalbraith (Kenneth H)
Anzahl der mitarbeiter280
WertpapierartOrdinary Share
GeschäftsjahresendeJun 24
Addresse108 Patriot Drive, Suite A
StadtMIDDLETOWN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl19709
Telefon13022748744
Websitehttps://www.zymeworks.com/
BörsenkürzelZYME
IPO-datumJun 24, 2019
CEOGalbraith (Kenneth H)

Führungskräfte von Zymeworks Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark Hollywood
Mr. Mark Hollywood
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
133.85K
+0.70%
Mr. Mark Hollywood
Mr. Mark Hollywood
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
133.85K
+0.70%
Mr. Mark Hollywood
Mr. Mark Hollywood
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
133.85K
+0.70%
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Dr. Paul A. Moore, Ph.D.
Dr. Paul A. Moore, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark Hollywood
Mr. Mark Hollywood
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
133.85K
+0.70%
Mr. Mark Hollywood
Mr. Mark Hollywood
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
133.85K
+0.70%
Mr. Mark Hollywood
Mr. Mark Hollywood
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
133.85K
+0.70%
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Zymeworks Inc?

Die fünf größten Anteilseigner von Zymeworks Inc sind: Mr. Mark Hollywood
tradingkey.logo
Risikohinweis: Unsere Website und mobile App bieten lediglich allgemeine Informationen zu bestimmten Anlageprodukten. Finsights stellt keine Finanzberatung oder Empfehlung für ein Anlageprodukt bereit, und die Bereitstellung solcher Informationen darf nicht als Finanzberatung durch Finsights ausgelegt werden.
Anlageprodukte unterliegen erheblichen Anlagerisiken, einschließlich des möglichen Verlusts des investierten Kapitals und sind möglicherweise nicht für jeden geeignet. Die vergangene Wertentwicklung von Anlageprodukten ist nicht unbedingt ein Hinweis auf deren zukünftige Wertentwicklung.
Finsights kann Drittanbietern oder Partnern erlauben, Werbung auf unserer Website oder in unserer mobilen App oder in Teilen davon zu platzieren oder bereitzustellen. Finsights kann für diese Anzeigenvergütung erhalten, basierend auf Ihrer Interaktion mit den Werbeanzeigen.
© Urheberrecht: FINSIGHTS MEDIA PTE. LTD. Alle Rechte vorbehalten.